Parsippany Chapter Upcoming Events Join PCCI

Monday, November 17, 2008

Embassy Suites, Chesterbrook, Pennsylvania (directions)

 

Solixia Inc.

An early-stage life science company

Presenter: Irene Susantio, Selixia’s Chief Executive Officer

About

 

Solixia Inc. is an early-stage life science company formed to develop better imaging and treatment options for aggressive cancer.  We are pioneering the fields of radioimmunodetection (RAID) and radioimmunotherapy (RAIT) in which radioactive compounds are injected into a patient for the purpose of visualizing or destroying tumors.  Our product candidates are based on a patented innovation in radiochemistry called the HotDot™ radiolabel, which was invented by the Company’s co-founder and Chief Science Officer.

 

A HotDot™ radiolabel is a compact cluster of radioactive atoms that can be delivered to tumor cells by antibody molecules for either imaging or treatment.  Relative to conventional radiolabels, it can increase the radioactive payload per antibody by 10X.  This will amplify the amount of diagnostic or therapeutic radioactivity that antibodies can deliver to tumors.  As a result, it will improve both imaging sensitivity, enabling earlier detection of small tumors, and therapeutic efficacy.

 

HotDot™ radiolabels have been developed for simple preparation using off-the-shelf reagents and readily available radioisotopes broadly used in nuclear medicine.  They can be visualized using a SPECT camera, a conventional medical imaging technology that is inexpensive to implement and already available in most every major hospital.

 

Solixia is presently raising $1.5 million in seed capital to perform preclinical proof-of-concept experiments in collaboration with the Fox Chase Cancer Center in Philadelphia.  Their initial commercialization effort is focused on two product candidates: a breast cancer imaging agent and a treatment for ovarian cancer.  They will pursue these indications through outlicensing or co-development partnerships with companies that own novel antitumor ligands.

 

 

3 Major Issues

 

  1. Solixia is negotiating an exclusive license to HotDot™ technology from the University of Pennsylvania.  What are reasonable licensing terms that would enable the company to raise funding and form partnerships?

  2. The greatest potential of Solixia’s technology may lie in orphan indications such as ovarian cancer.  How can management convince potential investors to invest in these small market opportunities?

  3. Are there promising in vitro (e.g. diagnostic) applications for radiochemicals such as HotDot™?

 

 

Program:

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Irene Susantio, Selixia’s Chief Executive Officer, will deliver the Company's "Elevator" Pitch to the Group

8:15 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests

 

 

<Top of the page>

 

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

Solixia's presentation to the group webcast and Q&A

Meeting date: 11/17/2008

Contact Info:

Irene Susantio
Chief Executive Officer

 

Solixia Inc.

408 Vance Hall

3733 Spruce Street

Philadelphia, PA 19104-6374

 

Tel: (215) 746.6512

Email: irene.susantio@solixia.com

Web: www.solixia.com

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc